Title:
ＢＣＬ－２阻害剤の適用及び老化関連皮膚病を治療するための薬物組成物
Document Type and Number:
Japanese Patent JP7378596
Kind Code:
B2
Abstract:
The present disclosure discloses use of a B-cell lymphoma 2 (BCL-2) inhibitor for treating aging-related skin diseases and a pharmaceutical composition for treating the aging-related skin diseases, belonging to the technical field of medicine. In the present disclosure, studies have found that pharmaceutical compositions containing the BCL-2 inhibitor can significantly ameliorate skin erythema and scale in imiquimod-induced psoriasis mouse models, significantly reduce a thickness of skin lesions, and decrease expression of aging-related proteins P16 and P21 and mRNA expression levels of p16, p21 and other genes in the skin lesions of the psoriasis mouse models. In addition, the pharmaceutical composition containing the BCL-2 inhibitor can significantly reduce infiltration of CD4+ T cells in dermis of the skin lesions of the psoriasis mouse models, and mRNA expression levels of skin lesion inflammatory factors such as IFN-γ, IL-17A, IL-22 and IL-23. Moreover, the pharmaceutical composition is superior to traditional intraperitoneal injection methods. It can be seen that the BCL-2 inhibitor and the pharmaceutical composition can effectively ameliorate the psoriasis mouse models, and have a prospect of developing into drugs for treating the psoriasis and the aging-related skin diseases.
Inventors:
land advance
Wu Kaiju
Zhu Huan
▲蒋▼嬌
Zhao Ming
Lee Wen-gun
Wu Kaiju
Zhu Huan
▲蒋▼嬌
Zhao Ming
Lee Wen-gun
Application Number:
JP2022516727A
Publication Date:
November 13, 2023
Filing Date:
October 19, 2021
Export Citation:
Assignee:
Suzhou Chung Yong Biopharmaceutical Co., Ltd.
Nanchang Angae Shensi Biomedical Co., Ltd.
Nanchang Angae Shensi Biomedical Co., Ltd.
International Classes:
A61K31/4965; A61K9/06; A61K9/08; A61K9/10; A61K9/70; A61K45/00; A61K47/02; A61K47/10; A61K47/12; A61K47/18; A61K47/20; A61K47/22; A61K47/26; A61K47/32; A61K47/34; A61K47/36; A61K47/38; A61P17/06
Domestic Patent References:
| JP2019142933A |
Foreign References:
| CN110623956A | ||||
| CN106163557A |
Other References:
LI, Keyou, et al.,Zanthoxylum bungeanum essential oil induces apoptosis of HaCaT human keratinocytes,Journal of Ethnopharmacology,2016年,Vol.186,pp.351-361
Attorney, Agent or Firm:
Maeda Suzuki International Patent Attorneys Corporation
Previous Patent: Fibrillated fiber and its manufacturing method
Next Patent: Preparing the training dataset using machine learning algorithms
Next Patent: Preparing the training dataset using machine learning algorithms